Effectiveness and Safety of Guselkumab for the Treatment of Psoriasis in Real-World Settings at 52 weeks: A Retrospective, Observational, Multicenter Study from China

Yang, Jing; Hu, Kun; Li, Xingyu; Hu, Jingjin; Tan, Minjia; Zhang, Mi; Kuang, Yehong; Lv, Chengzhi; Chen, Junchen

doi:10.1007/s13555-022-00869-w

Cited by 2 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No cases of serious adverse events were recorded. Real-life studies seem to confirm guselkumab's efficacy and safety in a real-world setting, while cases in China have been rarely assessed (5).…”

Section: Introductionmentioning

confidence: 99%

Long-term efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis

Zheng,

Chen,

et al. 2023

Front. Med.

View full text Add to dashboard Cite

BackgroundRandomized controlled trials indicated guselkumab, the first anti-interleukin-23 monoclonal antibody, is efficacious in plaque psoriasis. However, guselkumab's performance in real life is scarcely examined, especially in China.ObjectivesThis work aimed to assess the long-term effectiveness of guselkumab in actual clinical practice in China.MethodsA retrospective study was performed for plaque psoriasis cases administered guselkumab in Shanghai Skin Disease Hospital between January 2020 and September 2022.ResultsA total of 37 patients were included (29 men, 78.4%), with a mean follow-up period of 72.3 ± 26.7 weeks (range of 12–108 weeks). At baseline, clinical examination revealed a mean PASI of 12.3 ± 7.1, a mean BSA of 17.1 ± 18.1, and a mean DLQI of 7.7 ± 4.3. Twenty-two (62.9%) and 17 (48.6%) cases achieved PASI 90 and PASI 100 responses at week 28. From weeks 60 to 92, >80% of cases achieved PASI 90 and PASI 100 responses. Regarding safety, no cases of serious AEs were recorded. A total of nine cases (24.3%) had different abnormal results in HBV markers, and two were T-SPOT positive. There was no hepatitis B virus or tuberculosis outbreak in these patients.ConclusionThis real-life study confirmed the long-term efficacy and safety of guselkumab in daily clinical practice.

show abstract

Section: Introductionmentioning

confidence: 99%

Long-term efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis

Zheng,

Chen,

et al. 2023

Front. Med.

View full text Add to dashboard Cite

show abstract

The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials

Potestio,

Martora,

Lauletta

et al. 2024

CCID

View full text Add to dashboard Cite

Psoriasis pathogenesis is influenced by genetic factors and characterized by a complex interplay between genetic predisposition and various environmental triggers. These triggers set off metabolic processes involving inflammation, cell signaling, immune response dysregulation, and antigen presentation. Several types of innate and adaptive immune cells are involved in psoriasis. Among the cytokine cascade which leads to psoriasis development, the interleukin (IL)-23/Th17 axis, especially IL-17 production, emerges as crucial. Recognizing the pivotal role of this axis has facilitated the development of selective and effective biological drugs, such as anti-IL17 and anti-IL23 monoclonal antibodies. These drugs aim to achieve the complete or near-complete disappearance of psoriatic lesions, as indicated by PASI100 and PASI90 responses, respectively. In this context, the aim of our review was to delve into the functioning of the IL-23/Th17 axis, its dysregulation in psoriasis pathogenesis, and the therapeutic potential of its inhibition. Currently, 4 anti-IL17 (secukinumab, ixekizumab, bimekizumab and brodalumab) and 3 anti-IL23 (guselkumab, risankizumab and tildrakizumab) have been approved. All these drugs showed high levels of effectiveness in both clinical trials and real-life experiences, with an excellent profile in terms of safety. Certainly, furthers studies will allow for better characterization of biologics’ profile, in order to administer the right drug for the right patients at the right moment.

show abstract

Effectiveness and Safety of Guselkumab for the Treatment of Psoriasis in Real-World Settings at 52 weeks: A Retrospective, Observational, Multicenter Study from China

Cited by 2 publications

References 21 publications

Long-term efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis

Long-term efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis

The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials

Contact Info

Product

Resources

About